Equities

Check Cap Ltd

Check Cap Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.30
  • Today's Change0.003 / 0.14%
  • Shares traded7.75k
  • 1 Year change+53.00%
  • Beta0.1694
Data delayed at least 15 minutes, as of May 31 2024 17:55 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

  • Revenue in USD (TTM)0.00
  • Net income in USD-17.57m
  • Incorporated2009
  • Employees85.00
  • Location
    Check Cap Ltd29 Abba Hushi Ave., IsfiyaP.O.Box 1271 3009000IsraelISR
  • Phone+972 48303401
  • Fax+972 48211267
  • Websitehttps://check-cap.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Organovo Holdings Inc242.00k-19.09m12.77m15.00--1.56--52.78-2.17-2.170.02750.62830.0143--4.4412,100.00-112.40-51.24-123.59-54.90-----7,886.36-1,269.78----0.00---75.33-39.60-50.76--5.99--
Shineco Inc5.62m-14.34m12.89m87.00--0.3582--2.29-3.98-2.321.365.580.06640.481.4564,633.68-19.79-12.77-38.28-16.8412.7725.88-298.09-102.060.4842-8.140.3908-----58.35-33.86------
Kiora Pharmaceuticals Inc16.00m2.28m12.94m12.00--0.37095.570.809-1.60-1.601.211.330.5427--8.641,333,333.009.52-70.5210.17-81.86----17.55-2,040.61----0.00------3.97------
Nexgel Inc4.74m-3.20m12.95m19.00--2.71--2.74-0.5535-0.55350.82080.76880.44283.248.46249,263.20-30.72-44.61-39.92-56.1920.145.02-69.38-180.981.41--0.1819--99.6613.0633.48------
Actavia Life Sciences Inc0.00-406.65k13.04m1.00---------0.0005-0.00050.00-0.00280.00----0.00-805.97-158.17---------------5.63---------547.04------
Dominari Holdings Inc3.41m-24.56m13.12m26.00--0.2752--3.85-4.64-4.640.63058.030.0539--0.8023131,000.00-38.88-26.82-39.93-27.45-----721.11-3,353.52----0.00----135.7512.72--63.99--
Inhibikase Therapeutics Inc195.98k-19.20m13.28m8.00--1.76--67.75-3.38-3.380.0341.050.01--6.0824,497.50-97.88-66.49-118.76-85.55-----9,797.30-1,139.14----0.00--111.03-42.21-5.40------
Cell MedX Corp70.00-96.91k13.38m0.00------191,080.50-0.0029-0.00290.00-0.00240.0015-------202.28-792.55-----685.71---138,442.90-3,681.84---3.17-----54.53--29.01------
Pieris Pharmaceuticals Inc40.93m-16.25m13.40m46.00--0.5715--0.3274-12.74-12.7434.0517.760.7324--28.25889,717.40-29.09-28.41-52.98-39.69-----39.71-94.61----0.00--65.288.0326.25---36.82--
Check Cap Ltd0.00-17.57m13.42m85.00--0.5669-----3.00-3.000.004.050.00-------49.87-54.23-53.46-60.24------------0.00------8.06---2.46--
Imunon Inc0.00-18.85m13.54m33.00--1.59-----2.02-2.020.000.90410.00----0.00-66.82-50.18-91.53-60.27-------5,725.88----0.00---100.00--45.64--26.69--
Akari Therapeutics PLC (ADR)-100.00bn-100.00bn13.58m9.00---------------0.4449-----------149.95---435.18--------------------43.61------
Senti Biosciences Inc1.28m-86.11m13.73m48.00--0.2445--10.77-1.93-1.440.02851.230.0097--2.9426,562.50-65.33---71.42-------6,753.80------0.0018---40.25---67.94------
Edesa Biotech Inc0.00-7.25m13.93m16.00--3.22-----2.37-2.370.001.340.00----0.00-84.50---107.87--------------0.00------52.28------
CERo Therapeutics Holdings Inc0.00-2.54m14.01m8.00---------0.3796-0.37960.00-0.92260.00----0.00-9.96---33.80-----------------------279.82------
Data as of May 31 2024. Currency figures normalised to Check Cap Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.13%Per cent of shares held by top holders
HolderShares% Held
Morgan Stanley & Co. LLCas of 31 Mar 20243.44k0.06%
American Portfolios Advisors, Inc.as of 31 Mar 20241.61k0.03%
IFP Advisors, Inc.as of 31 Dec 2023500.000.01%
Securities America Advisors, Inc.as of 31 Mar 2024500.000.01%
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024300.000.01%
Qube Research & Technologies Ltd.as of 31 Mar 2024300.000.01%
Harbour Investments, Inc.as of 31 Dec 2023275.000.01%
Concourse Financial Group Securities, Inc.as of 31 Mar 2024213.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024156.000.00%
RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2024110.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.